🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Travere Therapeutics clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA, UK and Ireland registers with Travere Therapeutics as lead sponsor. Synced 26 Sep 2026
6Current trials
3Recruiting now
4Drugs in these trials
3Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Travere Therapeutics is the lead sponsor of 6 current clinical trials in our USA, UK and Ireland registers. 3 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Pegtibatinase, Sparsentan and Dapagliflozin. The most-studied condition is Homocystinuria.

ClinicalTrials.gov trials by status

  • Recruiting350%
  • Active, closed233%
  • By invitation117%

Trials by phase

  • Phase 3350%
  • Phase 2117%
  • Phase 1/2117%
  • Phase 4117%
01

Clinical trials sponsored by Travere Therapeutics

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085 · ClinicalTrials.gov ↗ · Homocystinuria
Phase 3 Recruiting 2023-12 Ireland, UK, USA
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
NCT05003986 · ClinicalTrials.gov ↗ · Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy
Phase 2 Recruiting 2021-08 UK, USA
Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)
NCT03406611 · ClinicalTrials.gov ↗ · Homocystinuria
Phase 1/2 Recruiting 2019-01 USA
A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
NCT06431893 · ClinicalTrials.gov ↗ · Homocystinuria
Phase 3 By invitation 2024-04 Ireland, UK, USA
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
NCT03762850 · Immunoglobulin A Nephropathy
Phase 3 Active, closed 2018-12 UK, USA
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
NCT07219121 · ClinicalTrials.gov ↗ · Proteinuria, Immunoglobulin A (IgA) Nephropathy, Focal Segmental Glomerulosclerosis
Phase 4 Active, closed 2025-10 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Travere Therapeutics trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Travere Therapeutics trials

8 conditions
Homocystinuria3Immunoglobulin A Nephropathy2Focal Segmental Glomerulosclerosis2Minimal Change Disease1IgA Vasculitis1Proteinuria1Immunoglobulin A (IgA) Nephropathy1Kidney Transplant1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA63
Clinical trials in UK42
Clinical trials in Ireland21

A trial with sites in more than one country appears in each of those registers.

05

Questions about Travere Therapeutics trials

How many clinical trials does Travere Therapeutics sponsor?

Travere Therapeutics is the lead sponsor of 6 current trials on ClinicalTrials.gov in our USA, UK and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Travere Therapeutics trials recruiting?

Yes. 3 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Travere Therapeutics testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Pegtibatinase (3), Sparsentan (3), Dapagliflozin (1) and Irbesartan (1). The number in brackets is how many of its trials name each drug.

Does Travere Therapeutics have clinical trials in Ireland?

Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.